» Articles » PMID: 34887680

How Well Do Current Laboratory Biomarkers Inform Clinical Decision-Making in Chronic Pain Management?

Overview
Journal J Pain Res
Publisher Dove Medical Press
Date 2021 Dec 10
PMID 34887680
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Decision-making in chronic pain patients involves a combination of subjective and objective criteria, including patient history, physical examination, imaging, and patient response to prior treatments, clinical experience, probabilities, and recognition of patterns. However, there is a distinct lack of objective laboratory biomarkers in use in routine clinical care. The objective was to review the literature to identify and describe specific biomarkers in chronic pain management.

Methods: This is a narrative review of the literature regarding the use of laboratory biomarkers in chronic pain. A librarian-assisted literature search of the PubMed, Science Direct, and Google Scholar databases was performed and resulted in 304 possible manuscripts. We included manuscripts assessing laboratory collected biomarkers from urine, serum, cerebrospinal fluid, and saliva. After screening and review of the initial literature search results, a total of 75 manuscripts were included in the narrative review.

Conclusion: The studies reviewed suggested that specific biomarkers may help identify those patients at risk of disease development and function as a prognostic indicator for disease progression and treatment response. However, additional research is necessary before specific recommendations can be made, and current clinical decision-making is modified.

Citing Articles

Effect of the novel anti-NGF monoclonal antibody DS002 on the metabolomics of pain mediators, cartilage and bone.

Jin D, Yang H, Chen Z, Hong Y, Ma H, Xu Z Front Pharmacol. 2024; 15:1396790.

PMID: 39188953 PMC: 11345146. DOI: 10.3389/fphar.2024.1396790.


Proteomics in Patients with Fibromyalgia Syndrome: A Systematic Review of Observational Studies.

Gkouvi A, Tsiogkas S, Bogdanos D, Gika H, Goulis D, Grammatikopoulou M Curr Pain Headache Rep. 2024; 28(7):565-586.

PMID: 38652420 PMC: 11271354. DOI: 10.1007/s11916-024-01244-4.


Shedding light on neuropathic pain: Current and emerging tools for diagnosis, screening, and quantification.

Hamdan A, Galvez R, Katati M SAGE Open Med. 2024; 12:20503121231218985.

PMID: 38343869 PMC: 10858674. DOI: 10.1177/20503121231218985.


Kynurenine Pathway Metabolites as Potential Biomarkers in Chronic Pain.

Auyeung A, Wang H, Aravagiri K, Knezevic N Pharmaceuticals (Basel). 2023; 16(5).

PMID: 37242464 PMC: 10224279. DOI: 10.3390/ph16050681.


Neuroendocrine Influencers and Associated Factors That Shape Jaw Movement and Growth in Temporomandibular Joint Disorder Management: A Systematic Review of Clinical and Radiographic Evidence.

Farook T, Dudley J J Pers Med. 2023; 13(5).

PMID: 37241010 PMC: 10221279. DOI: 10.3390/jpm13050840.

References
1.
Nam J, Lee H, Kim J, Kim J, Chu M . Salivary glutamate is elevated in individuals with chronic migraine. Cephalalgia. 2017; 38(8):1485-1492. DOI: 10.1177/0333102417742366. View

2.
Amirdelfan K, Pope J, Gunn J, Hill M, Cotten B, Beresh J . Clinical Validation of a Multi-Biomarker Assay for the Evaluation of Chronic Pain Patients in a Cross-Sectional, Observational Study. Pain Ther. 2020; 9(2):511-529. PMC: 7648807. DOI: 10.1007/s40122-020-00175-3. View

3.
Langan R, Goodbred A . Vitamin B12 Deficiency: Recognition and Management. Am Fam Physician. 2017; 96(6):384-389. View

4.
Lopez-Gonzalez M, Landry M, Favereaux A . MicroRNA and chronic pain: From mechanisms to therapeutic potential. Pharmacol Ther. 2017; 180:1-15. DOI: 10.1016/j.pharmthera.2017.06.001. View

5.
Backryd E . Pain in the Blood? Envisioning Mechanism-Based Diagnoses and Biomarkers in Clinical Pain Medicine. Diagnostics (Basel). 2016; 5(1):84-95. PMC: 4665549. DOI: 10.3390/diagnostics5010084. View